Brian Chia

About

🔹Senior Principal Scientist & Head of Peptide Chemistry at the Experimental Drug Development Centre (EDDC), A*STAR. 🔹I design & develop therapeutic peptides, peptidomimetics & new payloads for peptide drug conjugates (PDCs) and antibody drug conjugates (ADCs) for use as antibacterials, antifungals, antivirals and anti-cancer drugs. 🔹My team's most recent drug candidate is a peptidomimetic coronavirus protease inhibitor - licensed to Everest Medicines on 14 Jan 2022 (https://www.youtube.com/watch?v=AhnEFHqeSFk). Read more about this at: https://bit.ly/3qrHBj9 & https://lnkd.in/gysGTiy5 🔹Current projects: ❶ smart ADC payloads; ❷ antibacterial peptides

Experience

• Senior Principal Scientist & Head, Peptide Chemistry at Experimental Drug Development Centre (EDDC)
  Jan 2019 - Present · 7 yrs 6 mos

  ❶ Spearheading an antibody drug conjugate (ADC) project for cancers using a new payload. ❷ Co-inventor of an oral coronavirus main protease inhibitor - licensed to Everest Medicines for COVID-19 clinical trials in Jan 2022 (https://www.youtube.com/watch?v=AhnEFHqeSFk). Read more about it here: https://bit.ly/3qrHBj9 • Patent WO2022265577 ❸ Designing peptides with antibacterial properties in collaboration with research institutes and universities. ❹ Spearheaded a peptide-based anti-cancer project.

• Group Leader, Peptide Chemistry at A*STAR - Agency for Science, Technology and Research
  Jul 2007 - Dec 2018 · 11 yrs 6 mos

  ❶ Spearheaded development of an antibacterial preclinical development candidate for treating bacterial skin infections • US patents 10053490 & 10787483 ❷ Spalt-like transcription factor 4 peptides for treating cancer • US patent 10793601 ❸ Methyltransferase inhibitors for treating cancer • US patent application 20190071416 ❹ Bortezomib as an inhibitor of mycobacterial caseinolytic protease • WO2016127003 ❺ EIF4E binding peptides for treating cancer • US patents 9018348 & 9533023

• Research Scientist at Institute of Molecular and Cell Biology, A*STAR
  2005 - 2007 · 2 yrs

  Lead a team developing anti-cancer peptides with Professor Sir David Lane [https://en.wikipedia.org/wiki/David_Lane_(oncologist)]. ❶ Journal of Molecular Biology. 2011;405:736 DOI: 10.1016/j.jmb.2010.10.045 ❷ EIF4E binding peptides for treating cancer • US patents 9018348 & 9533023

• Postdoctoral Research Fellow at University of Cambridge
  2000 - 2002 · 2 yrs

  Studied drug-receptor interactions and antibiotics under Professor Sir Dudley Williams [https://en.wikipedia.org/wiki/Dudley_Williams_(biochemist)], Department of Chemistry. ❶ J. Am. Chem. Soc. 2002;124:3914 DOI: 10.1021/ja012273f ❷ FEBS Letters. 2002;512:47 DOI: 10.1016/S0014-5793(01)03313-0